A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer

European Journal of Cancer

Volumn 50, Issue 11, 2014, Pages 1909-1915

  Renouf, D J ^a   Tang, P A ^b   Hedley, D ^c   Chen, E ^c   Kamel Reid, S ^c   Tsao, M S ^c   Tran Thanh, D ^c   Gill, S ^a   Dhani, N ^c   Au, H J ^d   Wang, L ^c   Moore, M J ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

Author keywords

Erlotinib; Pancreatic cancer; Phase II

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIARRHEA; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOKALEMIA; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LARGE INTESTINE PERFORATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; THROMBOCYTOPENIA; TREATMENT DURATION;

ERLOTINIB; PANCREATIC CANCER; PHASE II;

ADULT; AGED; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84902257566     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.04.008     Document Type: Article

References (39)

1. A. Jemal, R. Siegel, and E. Ward et al. Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96
2. T. Conroy, F. Desseigne, and M. Ychou et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
3. H.A. Burris 3rd, M.J. Moore, and J. Andersen et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
4. M.H. Kulke, L.S. Blaszkowsky, and D.P. Ryan et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer J Clin Oncol 25 2007 4787 4792
5. P. Tang, S. Gill, and H.J. Au et al. Phase II trial of erlotinib in advanced pancreatic cancer J Clin Oncol 27 2009
6. D. Renouf, and M. Moore Evolution of systemic therapy for advanced pancreatic cancer Expert Rev Anticancer Ther 10 2010 529 540
7. M. Cantore, C. Rabbi, and G. Fiorentini et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer Oncology 67 2004 93 97
8. A. Demols, M. Peeters, and M. Polus et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br J Cancer 94 2006 481 485
9. H.Q. Xiong, G.R. Varadhachary, and J.C. Blais et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer Cancer 113 2008 2046 2052
10. K. Sudo, T. Yamaguchi, and K. Nakamura et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer Cancer Chemother Pharmacol 67 2011 249 254
11. B.M. Wolpin, A.F. Hezel, and T. Abrams et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer J Clin Oncol 27 2009 193 198
12. P.J. Hosein, G. de Lima Lopes Jr., and V.H. Pastorini et al. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer Am J Clin Oncol 36 2 2013 141 156
13. U. Pelzer, K. Kubica, and J. Stieler et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study J Clin Oncol 26 2008 [Abstr. 4508]
14. M.A. Tempero, J.P. Arnoletti, and S. Behrman et al. Pancreatic adenocarcinoma J Natl Compr Canc Netw 8 2010 972 1017
15. M.L. Fjallskog, M.H. Lejonklou, and K.E. Oberg et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors Clin Cancer Res 9 2003 1469 1473
16. H.Q. Xiong Molecular targeting therapy for pancreatic cancer Cancer Chemother Pharmacol 54 Suppl. 1 2004 S69 S77
17. S. Ueda, S. Ogata, and H. Tsuda et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: Poor prognosis in patients with pancreatic ductal adenocarcinoma Pancreas 29 2004 e1 e8
18. C.J. Bruns, C.C. Solorzano, and M.T. Harbison et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma Cancer Res 60 2000 2926 2935
19. S.S. Ng, M.S. Tsao, and T. Nicklee et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma Mol Cancer Ther 1 2002 777 783
20. M.J. Moore, D. Goldstein, and J. Hamm et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group J Clin Oncol 25 2007 1960 1966
21. R. Perez-Soler, A. Chachoua, and L.A. Hammond et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
22. R. Perez-Soler, and L. Saltz Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 23 2005 5235 5246
23. D. Soulieres, N.N. Senzer, and E.E. Vokes et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 2004 77 85
24. Chen EX, Zhang W, Pond GR, et al. Correlation between erlotinib concentrations and severity of skin rash. In: AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics; 2005.
25. T.S. Mok, Y.L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
26. C.Q. Zhu, G. da Cunha Santos, and K. Ding et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada clinical trials group study BR.21 J Clin Oncol 26 2008 4268 4275
27. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
28. D. Atkins, K.A. Reiffen, C.L. Tegtmeier, H. Winther, M.S. Bonato, and S. Störkel Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections J Histochem Cytochem 52 7 2004 893 901
29. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 1989 1 10
30. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
31. M. Peeters, S. Siena, and E. Van Cutsem et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy Cancer 115 2009 1544 1554
32. G. da Cunha Santos, N. Dhani, and D. Tu et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada clinical trials group study PA.3 Cancer 116 2010 5599 5607
33. PMID: 24356622.
34. Van Cutsem E, Nowara E, Ciuleanu T, et al. Dose escalation to rash for erlotinib plus gemcitabine in patients with metastatic pancreatic cancer: the phase II RACHEL (B021128) study. Ann of Oncol 23(Suppl. 4) [abstc 0006].
35. A.N. Hughes, M.E. O'Brien, and W.J. Petty et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers J Clin Oncol 27 2009 1220 1226
36. G.M. Clark, D.M. Zborowski, and P. Santabarbara et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada clinical trials group study BR.21 Clin Lung Cancer 7 2006 389 394
37. M. Hamilton, J.L. Wolf, and J. Rusk et al. Effects of smoking on the pharmacokinetics of erlotinib Clin Cancer Res 12 2006 2166 2171
38. J. Li, M. Zhao, and P. He et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes Clin Cancer Res 13 2007 3731 3737
39. S. Zevin, and N.L. Benowitz Drug interactions with tobacco smoking. An update Clin Pharmacokinet 36 1999 425 438